- Home
- JQC vs KALV Comparison
JQC vs KALV Comparison
Compare JQC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JQC
- KALV
- Stock Information
- Founded
- JQC 2003
- KALV N/A
- Country
- JQC United States
- KALV United States
- Employees
- JQC N/A
- KALV N/A
- Industry
- JQC Finance Companies
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- JQC Finance
- KALV Health Care
- Exchange
- JQC Nasdaq
- KALV Nasdaq
- Market Cap
- JQC 752.6M
- KALV 796.4M
- IPO Year
- JQC N/A
- KALV N/A
- Fundamental
- Price
- JQC $5.36
- KALV $13.88
- Analyst Decision
- JQC
- KALV Strong Buy
- Analyst Count
- JQC 0
- KALV 8
- Target Price
- JQC N/A
- KALV $26.43
- AVG Volume (30 Days)
- JQC 714.6K
- KALV 990.9K
- Earning Date
- JQC 01-01-0001
- KALV 09-11-2025
- Dividend Yield
- JQC 11.13%
- KALV N/A
- EPS Growth
- JQC N/A
- KALV N/A
- EPS
- JQC N/A
- KALV N/A
- Revenue
- JQC N/A
- KALV $1,426,000.00
- Revenue This Year
- JQC N/A
- KALV N/A
- Revenue Next Year
- JQC N/A
- KALV $213.43
- P/E Ratio
- JQC N/A
- KALV N/A
- Revenue Growth
- JQC N/A
- KALV N/A
- 52 Week Low
- JQC $4.82
- KALV $7.30
- 52 Week High
- JQC $5.65
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- JQC 33.72
- KALV 48.68
- Support Level
- JQC $5.48
- KALV $13.35
- Resistance Level
- JQC $5.58
- KALV $14.25
- Average True Range (ATR)
- JQC 0.04
- KALV 1.03
- MACD
- JQC -0.02
- KALV -0.15
- Stochastic Oscillator
- JQC 11.36
- KALV 16.05
About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.